Activity of docetaxel (Taxotere) in small cell lung cancer
| Autor: | S. B. Kaye, Jantien Wanders, Patrick Schöffski, H. R. Franklin, Cristiana Sessa, Jf Smyth, Ie Smith |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy Pathology business.industry medicine.medical_treatment Respiratory disease Neutropenia medicine.disease Small-cell carcinoma Metastasis chemistry.chemical_compound Docetaxel Paclitaxel chemistry Internal medicine medicine Carcinoma business medicine.drug |
| Zdroj: | European Journal of Cancer. 30:1058-1060 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(94)90455-3 |
| Popis: | Docetaxel (Taxotere) is a new cytotoxic compound with a broad spectrum of activity in preclinical studies. This paper reports a phase II trial in patients with previously-treated small cell carcinoma of the lung. 34 patients received 100 mg/m2 of docetaxel in an intravenous infusion given over 1 h every 21 days. Seven partial responses were reported (25% of 28 evaluable patients). Duration of response was 3.5-12.6 months. Toxicities were predominantly neutropenia, alopecia and asthenia. Docetaxel is a new compound with activity in previously-treated patients with small cell lung cancer, and is suitable for evaluation in combination with other cytotoxic drugs active in this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|